Hsbc Holdings PLC Has $1.36 Million Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

Hsbc Holdings PLC grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 91.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,929 shares of the biopharmaceutical company’s stock after buying an additional 27,739 shares during the period. Hsbc Holdings PLC’s holdings in Catalyst Pharmaceuticals were worth $1,362,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. Advisory Services Network LLC bought a new position in Catalyst Pharmaceuticals during the third quarter worth about $39,000. Quarry LP acquired a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter worth approximately $40,000. Clearstead Advisors LLC increased its holdings in shares of Catalyst Pharmaceuticals by 192.9% during the fourth quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 1,167 shares during the period. Smartleaf Asset Management LLC increased its holdings in shares of Catalyst Pharmaceuticals by 55.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 630 shares during the period. Finally, Larson Financial Group LLC raised its position in shares of Catalyst Pharmaceuticals by 552.7% in the fourth quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 1,564 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock opened at $31.47 on Monday. The firm has a market capitalization of $3.85 billion, a price-to-earnings ratio of 18.09, a PEG ratio of 0.96 and a beta of 0.74. The business’s 50-day moving average price is $31.24 and its 200-day moving average price is $26.78. Catalyst Pharmaceuticals, Inc. has a 12 month low of $19.05 and a 12 month high of $32.56.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. HC Wainwright cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $35.00 to $31.50 in a research note on Thursday, May 28th. Truist Financial upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, March 25th. Stephens set a $32.00 price target on Catalyst Pharmaceuticals in a research note on Thursday, May 7th. Zacks Research cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Finally, Citigroup downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $35.00 to $31.50 in a research note on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, Catalyst Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $32.00.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).